H.C. Wainwright analyst Mitchell Kapoor lowered the firm’s price target on Rani Therapeutics to $16 from $20 and keeps a Buy rating on the shares post the Q3 report. The analyst continues to view Rani as highly undervalued compared to similar historical drug delivery precedents.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on RANI:
- Rani Therapeutics announces development of RT-101 cancelled, 25% workforce cut
- Rani Therapeutics sees Q3 net loss $17M -$19M
- Rani Therapeutics Reports Third Quarter 2023 Financial Results; Provides Corporate Update
- Rani Therapeutics sees Q3 net loss $17M-$19M vs $16.2M last year
- Rani Therapeutics announces preclinical data on RaniPill platform
